Balancing Myocardial Ischemic and Bleeding Risks in Patients With Non-ST-Segment Elevation Myocardial Infarction

American Journal of Cardiology

Volumn 103, Issue 10, 2009, Pages 1396-1402

  Díez, José G ^a,b   Cohen, Marc ^c,d  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; ST SEGMENT ELEVATION; VALIDATION PROCESS;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK ASSESSMENT;

EID: 65449154052     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.349     Document Type: Review

References (41)

1. Alexander K.P., Chen A.Y., Roe M.T., Newby L.K., Gibson C.M., Allen-LaPointe N.M., Pollack C., Gibler W.B., Ohman E.M., Peterson E.D., and CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
2. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey Jr. D.E., Chavey II W.E., Fesmire F.M., Hochman J.S., Levin T.N., et al., American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction), American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50 (2007) e1-e157
3. Boden W.E., Hoekstra J., and Miller C.D. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. Am J Emerg Med 26 (2008) 212-220
4. Cohen M., Antman E.M., Murphy S.A., and Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Am Heart J 143 (2002) 63-69
5. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., Neumann F.J., Robertson D.H., DeLucca P.T., DiBattiste P.M., et al., TACTICS (Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy)-Thrombolysis In Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
6. Antman E.M., Cohen M., Bernink P.J., McCabe C.H., Horacek T., Papuchis G., Mautner B., Corbalan R., Radley D., and Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 (2000) 835-842
7. Granger C.B., Goldberg R.J., Dabbous O., Pieper K.S., Eagle K.A., Cannon C.P., Van De Werf F., Avezum A., Goodman S.G., Flather M.D., Fox K.A., and Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
8. Boersma E., Pieper K.S., Steyerberg E.W., Wilcox R.G., Chang W.C., Lee K.L., Akkerhuis K.M., Harrington R.A., Deckers J.W., Armstrong P.W., et al., PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 101 (2000) 2557-2567
9. Morrow D.A., Antman E.M., Snapinn S.M., McCabe C.H., Theroux P., and Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 23 (2002) 223-229
10. Pollack Jr. C.V., Sites F.D., Shofer F.S., Sease K.L., and Hollander J.E. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. Acad Emerg Med 13 (2006) 13-18
11. Alexander J.H., Harrington R.A., Tuttle R.H., Berdan L.G., Lincoff A.M., Deckers J.W., Simoons M.L., Guerci A., Hochman J.S., Wilcox R.G., et al., PURSUIT Investigators. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 83 (1999) 1147-1151
12. Sabatine M.S., McCabe C.H., Morrow D.A., Giugliano R.P., de Lemos J.A., Cohen M., Antman E.M., and Braunwald E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J 143 (2002) 966-970
13. Kini A.S., Lee P.C., Mitre C.A., Kim M.C., Kamran M., Duffy M.E., Marmur J.D., and Sharma S.K. Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome. Am J Med 115 (2003) 708-714
14. Mega J.L., Morrow D.A., Sabatine M.S., Zhao X.Q., Snapinn S.M., DiBattiste P.M., Gibson C.M., Antman E.M., Braunwald E., and Théroux P. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J 149 (2005) 846-850
15. Morrow D.A., Antman E.M., Giugliano R.P., Cairns R., Charlesworth A., Murphy S.A., de Lemos J.A., McCabe C.H., and Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358 (2001) 1571-1575
16. Wiviott S.D., Morrow D.A., Frederick P.D., Antman E.M., Braunwald E., and National Registry of Myocardial Infarction. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 47 (2006) 1553-1558
17. de Araújo Gonçalves P., Ferreira J., Aguiar C., and Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 26 (2005) 865-872
18. Eagle K.A., Lim M.J., Dabbous O.H., Pieper K.S., Goldberg R.J., Van de Werf F., Goodman S.G., Granger C.B., Steg P.G., Gore J.M., et al., GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (2004) 2727-2733
19. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339 (1998) 436-443
20. Yan A.T., Yan R.T., Tan M., Casanova A., Labinaz M., Sridhar K., Fitchett D.H., Langer A., and Goodman S.G. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 28 (2007) 1072-1078
21. Januzzi Jr. J.L., Newby L.K., Murphy S.A., Pieper K., Antman E.M., Morrow D.A., Sabatine M.S., Ohman E.M., Cannon C.P., and Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J 151 (2006) 360-366
22. Karounos M., Chang A.M., Robey J.L., Sease K.L., Shofer F.S., Follansbee C., and Hollander J.E. TIMI risk score: does it work equally well in both males and females?. Emerg Med J 24 (2007) 471-474
23. Manoukian S.V., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., Dangas G.D., Lincoff A.M., White H.D., Moses J.W., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Cardiol 49 (2007) 1362-1368
24. Moscucci M., Fox K.A., Cannon C.P., Klein W., López-Sendón J., Montalescot G., White K., and Goldberg R.J. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
25. Subherwal S., Bach R.G., Chen A.Y., Gage B.F., Rao S.V., Wang T.Y., Gibler W.B., Ohman E.M., Roe M.T., Peterson E.D., and Alexander K.P. The CRUSADE bleeding score to assess baseline risk of major bleeding in non-S.T.-segment elevation myocardial infarction. http://www.cardiosource.com/img/subherwal_CRUSADE.ppt Accessed July 18, 2008
26. Chew D.P., Lincoff A.M., Gurm H., Wolski K., Cohen D.J., Henry T., Feit F., Topol E.J., and REPLACE-2 Investigators. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95 (2005) 581-585
27. Doyle B.J., Ting H.H., Bell M.R., Lennon R.J., Mathew V., Singh M., Holmes D.R., and Rihal C.S. Major femoral bleeding complications after percutaneous coronary intervention: Incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. J Am Coll Cardiol Interv 1 (2008) 202-209
28. Aguirre F.V., Topol E.J., Ferguson J.J., Anderson K., Blankenship J.C., Heuser R.R., Sigmon K., Taylor M., Gottlieb R., Hanovich G., et al., EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 91 (1995) 2882-2890
29. Kinnaird T.D., Stabile E., Mintz G.S., Lee C.W., Canos D.A., Gevorkian N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
30. Sadeghi H.M., Stone G.W., Grines C.L., Mehran R., Dixon S.R., Lansky A.J., Fahy M., Cox D.A., Garcia E., Tcheng J.E., et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108 (2003) 2769-2775
31. LaPointe N.M., Chen A.Y., Alexander K.P., Roe M.T., Pollack Jr. C.V., Lytle B.L., Ohman M.E., Gibler B.W., and Peterson E.D. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch Intern Med 167 (2007) 1539-1544
32. Denardo S.J., Davis K.E., and Tcheng J.E. Reduced-dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention. Am J Cardiol 100 (2007) 1376-1382
33. Anand S.S., Yusuf S., Pogue J., Ginsberg J.S., Hirsh J., and Organization to Assess Strategies for Ischemic Syndromes Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 107 (2003) 2884-2888
34. Steinberg D.H., Shah P., Kinnaird T., Pinto Slottow T.L., Roy P.K., Okabe T., Bonello L., de Labriolle A., Smith K.A., Torguson R., et al. Bleeding risk and outcomes of bivalirudin versus glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Am J Cardiol 102 (2008) 160-164
35. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bittl J.A., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al., REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
36. Helft G., Gilard M., Le Feuvre C., and Zaman A.G. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 3 (2006) 673-680
37. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., Mahaffey K.W., Califf R.M., and Harrington R.A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
38. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
39. Spencer F.A., Moscucci M., Granger C.B., Gore J.M., Goldberg R.J., Steg P.G., Goodman S.G., Budaj A., FitzGerald G., Fox K.A., and GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 116 (2007) 2793-2801
40. Nikolsky E., Mehran R., Dangas G., Fahy M., Na Y., Pocock S.J., Lincoff A.M., and Stone G.W. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 28 (2007) 1936-1945
41. Montalescot G., Steg P.G., Cohen M., White H., Gallo R., Steinhubl S.R., and STEEPLE Investigators. Development and validation of a bleeding risk model for major bleeding in patients undergoing elective percutaneous coronary intervention: the STEEPLE trial. [abstract]. Circulation 114 (2006) II_648